Millennium Management’s Celldex Therapeutics CLDX Stock Holding History

Millennium Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-21,400	Closed	-$727K	–	6011
2024 Q3	$727K	Buy	+21,400	New	+$815K	﹤0.01%	4530
2022 Q3	–	Sell	-116,200	Closed	-$3.13M	–	7103
2022 Q2	$3.13M	Buy	+116,200	New	+$3.37M	﹤0.01%	3249
2014 Q1	–	Sell	-2,333	Closed	-$847K	–	3486
2013 Q4	$847K	Buy	+2,333	New	+$899K	﹤0.01%	2382

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management's CLDX Position: Q2 2026 in Review

Millennium Management reduced its Celldex Therapeutics (CLDX) stake by 6.6% in Q2 2026, selling an estimated $2.67M and leaving 1,170,787 shares worth $43.6M. The position accounts for 0.02% of the portfolio, ranked #984.

Millennium Management first reported a position in CLDX in Q2 2013 and has held it in 42 quarters since. The position peaked at $57.7M in Q1 2015. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Millennium Management held 1,170,787 shares of Celldex Therapeutics worth $43.6M as of Q2 2026.
Millennium Management sold 82,745 Celldex Therapeutics shares in Q2 2026, an estimated $2.67M.
Celldex Therapeutics made up 0.02% of Millennium Management's portfolio in Q2 2026, its #984 holding.
Millennium Management first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 42 quarters since.
Millennium Management's Celldex Therapeutics position peaked at $57.7M in Q1 2015.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.